Carbamates for use as sarm1 inhibitors
Carbamate compounds are developed to inhibit the SARM1 protein, addressing the inadequacies of current treatments for axonal degeneration-related disorders, offering therapeutic benefits for conditions like ALS and MS.
HK40134865APending Publication Date: 2026-07-10GENENTECH INC
0 Cites 0 Cited by
Patent Information
- Application Number
- HK62026124293
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-08-15
- Filing Date
- 2026-06-03
- Publication Date
- 2026-07-10
AI Technical Summary
Technical Problem
Current treatments for neurological disorders associated with axon degeneration, such as peripheral neuropathy and neurodegenerative diseases, are inadequate in effectively inhibiting the SARM1 protein, leading to significant health and economic burdens.
Method used
Development of carbamate compounds that inhibit the SARM1 protein, which are administered to treat conditions characterized by axonal degeneration, including neurodegenerative diseases like ALS, CIPN, and MS, through oral or injection routes.
Benefits of technology
The carbamate compounds effectively inhibit SARM1, potentially reducing axonal degeneration and alleviating symptoms of associated neurological disorders, providing a therapeutic benefit for affected individuals.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention relates to carbamate compounds of formula (I), as further detailed herein, for use in inhibiting the SARM1 protein, as well as compositions comprising these compounds and methods of treatment by administration of the compounds and compositions.
Need to check novelty before this filing date? Find Prior Art